Blue Sky Biotech, Inc Names Dr. Norman Garceau, Former Scientist at Pfizer Global Research and Development, as Chief Scientific Officer
Worcester, MA, March 15, 2006 --(
PR.com)-- Blue Sky Biotech, Inc. announced the Feb 1st appointment of
Norman Garceau, Ph.D., as Chief Scientific Officer. Dr. Garceau previously worked in early drug discovery at the Pfizer Research Technology Center (Cambridge, MA) from 1999 to 2006, engaged in a range of activities that included gene cloning and expression profiling, cell biology, assay development, and lead discovery. Prior to joining Pfizer, Dr. Garceau was a Research Assistant Professor in the Department of Immunology at Dartmouth Medical School (1998-1999), a Postdoctoral Fellow at Pfizer Global Research and Development (1996-1998), and a manager at Upstate Biotechnology (1987-1990). He earned a Ph.D from the Department of Biochemistry at Dartmouth College (1990-1996).
“We are delighted to gain an executive with the groundbreaking pharmaceutical research background of Norm Garceau”, said
Paul Wengender, M.S., MBA, Blue Sky Biotech President and Director of Business Development. “His first hand understanding of the needs of major pharmaceutical and biotechnology research organizations will help us continue to grow our industry-leading contract research services. We are pleased to welcome Norm to the Blue Sky Biotech community.” As Chief Scientific Officer, Dr. Garceau will play a key leadership role in the specific areas of cellular and molecular biology services, strategic technology alliances, and product development.
The Company
Blue Sky Biotech, Inc. is an integrated service provider of “Gene To Screen” discovery biologicals. Currently, Blue Sky offers 3 linked laboratory service segments: Molecular Biology, Tissue Culture/Fermentation, and Protein Sciences (including biochemistry). This pre-clinical contract service bundle offers research-based drug discovery clients a convenient source of pharma-grade research tools. Services include Gene Synthesis, Vector Construction, Recombinant Protein Expression (bacterial, yeast, mammalian, insect), Stable Cell production, Protein Purification, and Assay Development. Blue Sky’s premium baculoviral (insect cell recombinant protein expression) service boasts a proprietary process technology (IKM®) that significantly improves turnaround time and enhances reproducibility. The Company is a privately held corporation, with 16 staff members. Blue Sky is located in Worcester, MA.
www.blueskybiotech.com
###
